Issue Date: March 26, 2007
Lilly Ups Commitment To Fight Tuberculosis
Eli Lilly & Co. is investing another $50 million in the Lilly MDR-TB Partnership, a consortium of 14 public and private organizations aligned to battle multi-drug-resistant tuberculosis. The cash influx brings Lilly's total investment in the project during the past four years to $120 million. Lilly also has provided several generic drugmakers with manufacturing and formulation technology needed to produce capreomycin and cycloserine, two Lilly antibiotics used to treat MDR-TB. In conjunction with Lilly's donation, the firms participating in the alliance will work to ramp up supplies of the antibiotics.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society